Elevance Health (ELV) is strategically positioned for margin restoration and earnings growth following a disciplined 2025 reset, where management proactively lowered guidance to set a clear path for future improvement. The company's Carelon platform continues to drive robust, diversified revenue streams, complementing strong overall revenue growth and consistent capital returns. With ELV trading at an attractive valuation discount relative to peers and demonstrating stronger profitability metrics, the company is expected to achieve earnings normalization into 2026, supported by operational efficiencies and its multi-pillar business model, as evidenced by its recent breakout above $300 resistance.
Elevance Health is emerging from a 2025 reset with improved positioning to restore margins and grow its earnings base. Management has demonstrated discipline by lowering guidance to reflect elevated costs rather than delaying recognition, clearing the decks for the future. At the same time, the Carelon platform continues to deliver robust growth, diversifying revenue streams beyond traditional insurance underwriting. With revenue growth still strong, ongoing capital returns, and valuation at a discount to peers, Elevance is positioned for earnings normalization into 2026, supported by its multi-pillar business model. Trade timing & outlook ELV recently broke out above its $300 resistance level, showing relative strength versus the health care sector and the S & P 500. This breakout suggests potential institutional accumulation after the 2025 reset, with potential upside towards our $425 target. Fundamentals Relative to the industry, ELV remains attractively valued while delivering stronger profitability: Forward PE ratio: 11x vs. Industry 11x Expected EPS growth: 6% vs. 9% Expected revenue growth: 7% vs. 6% Net margins: 3% vs. 2% Bullish thesis Positioned for 2026 recovery: By cutting guidance, management has set a lower base, clearing the path for margin improvement in 2026 through pricing and benefit adjustments. Diversification through Carelon: Pharmacy and Services continue to expand rapidly, with risk-based arrangements scaling to provide durable, fee-based earnings that offset underwriting cyclicality. Operational efficiency: Automation of prior authorizations and advanced analytics to curb waste strengthen cost-control initiatives that can improve medical trends. Capital return discipline: Despite the reset, Elevance delivered $49.4B in operating revenue and returned $2 billion year to date in buybacks and dividends, reinforcing balance sheet strength. Options trade With an IV Rank of 74%, options are expensive, making vertical call spreads attractive to reduce premium outlay and improve our risk to reward. I’m buying the Dec. 19 $360/$420 Call Vertical @ $19.10 Debit. This entails: Buying the Dec. 19 $360 call @ $27.40 Selling the Dec. 19 $420 call @ $8.30 The maximum reward per contract is $4,090 if ELV is above $420 at expiration. The maximum risk per contract is $1,910 if ELV is below $360 at expiration. The breakeven point for this strategy is $379.10. View this trade with updated prices at OptionsPlay . This debit vertical spread structure captures potential upside from Elevance’s margin recovery and Carelon-led diversification, with a reward-to-risk ratio that is greater than 2 to 1 as the company emerges from its 2025 reset positioned for improved profitability. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer. Elevance Health (ELV) is strategically positioned for margin restoration and earnings growth following a disciplined 2025 reset. Management's proactive lowering of guidance to reflect elevated costs is viewed as clearing the path for future margin improvement and earnings normalization into 2026. This move demonstrates a commitment to setting a realistic base for recovery through pricing and benefit adjustments. The Carelon platform is a significant growth engine, delivering robust, diversified revenue streams that complement traditional insurance underwriting and provide durable, fee-based earnings. ELV reported strong operating revenue of $49.4 billion and demonstrated capital return discipline with $2 billion in buybacks and dividends year-to-date, underpinning its financial strength and multi-pillar business model. Despite the reset, ELV maintains an attractive valuation, trading at an 11x forward P/E, on par with the industry, but with superior net margins of 3% versus the industry's 2%. The stock recently broke out above its $300 resistance level, indicating relative strength against the broader healthcare sector and S&P 500, suggesting potential institutional accumulation and a bullish outlook towards a $425 target.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
